{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:34:23Z","timestamp":1788003263612,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The underlying mechanisms of chemotherapy-induced gastrointestinal (GI) symptoms are poorly researched. This study characterised the nature, frequency, severity and treatable causes for GI symptoms prospectively in patients undergoing chemotherapy for GI malignancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients receiving chemotherapy for a GI malignancy were assessed pre-chemotherapy, then monthly for 1\u00a0year using the Gastrointestinal Symptom Rating Scale, a validated patient-reported outcome measure. Patients with new, troublesome GI symptoms were offered investigations to diagnose the cause(s). Their oncologist was alerted when investigations were abnormal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 241 patients, 60% male, median age 63\u00a0years (range 30\u201388), were enrolled; 122 patients were withdrawn, 93%, because of progressive disease or death. During the study, &gt;\u200920% patients reported chronic faecal incontinence and &gt;\u200910% reported moderate or severe problems with taste, dysphagia, belching, heartburn, early satiety, appetite, nausea, abdominal cramps, peri-rectal pain, rectal flatulence, borborygmi, urgency of defecation or tenesmus. Thirty percent reported continuing passage of hard stools and 30% on-going diarrhoea. Moderate or severe fatigue affected 40% participants at its peak and persisted in 15% at 1\u00a0year. Toxicity dictated change in chemotherapy for 13\u201329% patients\/month. Common Terminology Criteria for Adverse Events underestimated gastrointestinal morbidity. Pre-chemotherapy screening identified previously undiagnosed pathology: exocrine pancreatic insufficiency (9%), vitamin B<jats:sub>12<\/jats:sub> deficiency (12%) and thyroid dysfunction (20%). Patients often refused investigations to diagnose their chemotherapy-induced symptoms; however, for every three investigations performed, one treatable cause was diagnosed: particularly small intestinal bacterial overgrowth (54%), bile acid malabsorption (43%), previously not described after chemotherapy, and unsuspected urinary tract infection (17%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients undergoing chemotherapy for GI malignancy commonly have difficult GI symptoms requiring active management which does not occur routinely. The underlying causes for these symptoms are often treatable or curable. Randomised trials are urgently needed to show whether timely investigation and treatment of symptoms improve quality of life and survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link> Identifier: NCT02121626<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-020-05610-x","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T08:03:36Z","timestamp":1594886616000},"page":"1443-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-6352","authenticated-orcid":false,"given":"H. Jervoise N.","family":"Andreyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amyn","family":"Lalji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C. G.","family":"Muls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Pitkaaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Caley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Pittordou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wedlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"5610_CR1","unstructured":"https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence. 2018 ["},{"issue":"10","key":"5610_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2015.65.7973","volume":"34","author":"S Grover","year":"2016","unstructured":"Grover S, Lim RM, Blumberg RS, Syngal S (2016) Oncogastroenterology. J Clin Oncol 34(10):1154\u20131155","journal-title":"J Clin Oncol"},{"issue":"10","key":"5610_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.clon.2007.08.008","volume":"19","author":"P Vicary","year":"2007","unstructured":"Vicary P, Johnson M, Maher J (2007) Patient representatives of the Macmillan Late Effects Project Group. To my oncologist - an open letter from a patient at the end of follow-up. Clin Oncol (R Coll Radiol) 19(10):746\u2013747","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"5610_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00280-008-0732-8","volume":"63","author":"RM Logan","year":"2009","unstructured":"Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DMK (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63:239\u2013251","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"5610_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/MIB.0b013e318280e75f","volume":"19","author":"B Lemmens","year":"2013","unstructured":"Lemmens B, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M et al (2013) Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 19(6):1194\u20131201","journal-title":"Inflamm Bowel Dis"},{"issue":"9910","key":"5610_CR6","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(13)61648-7","volume":"382","author":"HJN Andreyev","year":"2013","unstructured":"Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO (2013) Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet 382(9910):2084\u20132092","journal-title":"Lancet"},{"issue":"1","key":"5610_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ecc.12766","volume":"27","author":"AC Muls","year":"2018","unstructured":"Muls AC, Klimova K, Andreyev HJN (2018) Clinical decision-making in managing changes in gastrointestinal function following cancer therapies: is experience enough? Eur J Cancer Care (Engl) 27(1):1\u20134","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"5610_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7861\/clinmedicine.16-3-240","volume":"16","author":"AC Muls","year":"2016","unstructured":"Muls AC, Lalji A, Marshall C, Butler L, Shaw C, Vyoral S, Mohammed K, Andreyev HJN (2016) The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem? Clin Med 16(3):240\u2013246","journal-title":"Clin Med"},{"issue":"8","key":"5610_CR9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00520-013-1782-y","volume":"21","author":"CC Henson","year":"2013","unstructured":"Henson CC, Davidson SE, Ang Y, Babbs C, Crampton J, Kelly M, Lal S, Limdi JK, Whatley G, Swindell R, Makin W, McLaughlin J (2013) Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy. Support Care Cancer 21(8):2255\u20132265","journal-title":"Support Care Cancer"},{"issue":"15","key":"5610_CR10","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","volume":"124","author":"C Pawlyn","year":"2014","unstructured":"Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, Morgan GJ, Andreyev HJN (2014) Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 124(15):2467\u20132468","journal-title":"Blood."},{"key":"5610_CR11","unstructured":"Hassan B, Lightowlers S, Matakidou A, Eisen T, Fife K, Cameron E. Bile acid malabsorption is a common, reversible cause of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma (abstract). http:\/\/abstractsncriorguk\/abstract\/bile-acid-malabsorption-is-a-common-reversible-cause-of-diarrhoea-in-patients-on-tyrosine-kinase-inhibitors-for-metastatic-renal-cell-carcinoma-2\/. 2015"},{"issue":"4","key":"5610_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrgastro.2018.14","volume":"15","author":"MA Samaan","year":"2018","unstructured":"Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM (2018) Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol 15(4):222\u2013234","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"5610_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund J, Sj\u00f6din I, Dotevall G (1988) GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33(2):129\u2013134","journal-title":"Dig Dis Sci"},{"issue":"9","key":"5610_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920\u2013924","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"5610_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/gut.44.1.77","volume":"44","author":"CJ Vaizey","year":"1999","unstructured":"Vaizey CJ, Carapeti E, Cahill JA, Kamm MA (1999) Prospective comparison of faecal incontinence grading systems. Gut. 44(1):77\u201380","journal-title":"Gut."},{"key":"5610_CR16","unstructured":"http:\/\/www.facit.org\/LiteratureRetrieve.aspx?ID=42149 ["},{"key":"5610_CR17","unstructured":"https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf ["},{"issue":"1","key":"5610_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/flgastro-2014-100468","volume":"6","author":"HJN Andreyev","year":"2015","unstructured":"Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO (2015) The practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol 6(1):53\u201372","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"5610_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/flgastro-2016-100714","volume":"8","author":"HJN Andreyev","year":"2017","unstructured":"Andreyev HJN, Muls AC, Shaw C, Jackson RR, Gee C, Vyoral S, Davies AR (2017) Guide to managing persistent upper gastrointestinal symptoms during and after treatment for cancer. Frontline Gastroenterol 8(4):295\u2013323","journal-title":"Frontline Gastroenterol"},{"issue":"Supplement 4","key":"5610_CR20","doi-asserted-by":"publisher","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","volume":"29","author":"P Bossi","year":"2018","unstructured":"Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F et al (2018) Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 29(Supplement 4):iv126\u2013iiv42","journal-title":"Ann Oncol"},{"issue":"8","key":"5610_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1542-3565(04)00293-9","volume":"2","author":"P Osterlund","year":"2004","unstructured":"Osterlund P, Ruotsalainen T, Peuhkuri K, Korpela R, Ollus A, Ikonen M et al (2004) Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2(8):696\u2013703","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"5610_CR22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3892\/mco.2015.635","volume":"3","author":"SF Lee","year":"2015","unstructured":"Lee SF, Chiang CL, Lee AS, Wong FC, Tung SY (2015) Severe ileitis associated with capecitabine: two case reports and review of the literature. Mol Clin Oncol 3(6):1398\u20131400","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"5610_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2468-1253(18)30159-6","volume":"3","author":"KB Gecse","year":"2018","unstructured":"Gecse KB, Vermeire S (2018) Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 3(9):644\u2013653","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"5610_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2468-1253(18)30264-4","volume":"3","author":"R Fish","year":"2018","unstructured":"Fish R, Sanders C, Adams R, Brewer J, Brookes ST, DeNardo J, Kochhar R, Saunders MP, Sebag-Montefiore D, Williamson PR, Renehan AG (2018) A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol 3(12):865\u2013873","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"5610_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3109\/0284186X.2012.731521","volume":"52","author":"CD Amdal","year":"2013","unstructured":"Amdal CD, Jacobsen AB, Guren MG, Bjordal K (2013) Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol 52(4):679\u2013690","journal-title":"Acta Oncol"},{"key":"5610_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.radonc.2008.09.019","volume":"90","author":"A Capp","year":"2009","unstructured":"Capp A, Inostroza-Ponta M, Bill D, Moscato P, Lai C, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North J, Poulsen M, Spry NA, Tai KH, Wynne C, Duchesne G, Steigler A, Denham JW (2009) Morbidity of prostate radiotherapy: is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol 90:400\u2013407","journal-title":"Radiother Oncol"},{"issue":"4","key":"5610_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2036.2007.03405.x","volume":"26","author":"C Gillespie","year":"2007","unstructured":"Gillespie C, Goode C, Hackett C, Andreyev HJN (2007) The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 26(4):555\u2013563","journal-title":"Aliment Pharmacol Ther"},{"key":"5610_CR28","doi-asserted-by":"publisher","unstructured":"Chen TY, Emmertsen KJ, Laurberg S (2013) Bowel dysfunction after rectal cancer treatment: a study comparing the specialist\u2019s versus patient\u2019s perspective. BMJ Open 4:e003374. https:\/\/doi.org\/10.1136\/bmjopen-2013-003374","DOI":"10.1136\/bmjopen-2013-003374"},{"issue":"14","key":"5610_CR29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","volume":"32","author":"G Kotronoulas","year":"2014","unstructured":"Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32(14):1480\u20131501","journal-title":"J Clin Oncol"},{"issue":"5","key":"5610_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/apt.13283","volume":"42","author":"R Sood","year":"2016","unstructured":"Sood R, Gracie DJ, Law GR, Ford AC (2016) Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and\/or psychological markers. Aliment Pharmacol Ther 42(5):491\u2013503","journal-title":"Aliment Pharmacol Ther"},{"key":"5610_CR31","doi-asserted-by":"publisher","unstructured":"Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J et al (2017) Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9). https:\/\/doi.org\/10.1093\/jnci\/djx029","DOI":"10.1093\/jnci\/djx029"},{"issue":"2","key":"5610_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 318(2):197\u2013198","journal-title":"JAMA."},{"issue":"8","key":"5610_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1200\/JCO.2016.70.5046","volume":"35","author":"JS Temel","year":"2017","unstructured":"Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA et al (2017) Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 35(8):834\u2013841","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05610-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:07:03Z","timestamp":1626394023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05610-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5610"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05610-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}